-
1
-
-
84954400636
-
Cancer statistics, 2016
-
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7-30 (2016).
-
(2016)
CA Cancer J. Clin.
, vol.66
, pp. 7-30
-
-
Siegel, R.L.1
Miller, K.D.2
Jemal, A.3
-
2
-
-
84877028141
-
Comprehensive molecular portraits of human breast tumours
-
Cancer Genome Atlas Network
-
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
-
(2012)
Nature
, vol.490
, pp. 61-70
-
-
-
3
-
-
0035881617
-
Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns
-
Gruvberger, S. et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 61, 5979-5984 (2001).
-
(2001)
Cancer Res.
, vol.61
, pp. 5979-5984
-
-
Gruvberger, S.1
-
4
-
-
0035845511
-
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
-
Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
-
(2001)
Proc. Natl Acad. Sci. USA
, vol.98
, pp. 10869-10874
-
-
Sorlie, T.1
-
5
-
-
0036798273
-
Molecular prognostic factors for breast cancer metastasis and survival
-
Esteva, F. J., Sahin, A. A., Cristofanilli, M., Arun, B. & Hortobagyi, G. N. Molecular prognostic factors for breast cancer metastasis and survival. Semin. Radiat. Oncol. 12, 319-328 (2002).
-
(2002)
Semin. Radiat. Oncol.
, vol.12
, pp. 319-328
-
-
Esteva, F.J.1
Sahin, A.A.2
Cristofanilli, M.3
Arun, B.4
Hortobagyi, G.N.5
-
6
-
-
77954526150
-
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
-
Hammond, M. E. et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784-2795 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 2784-2795
-
-
Hammond, M.E.1
-
7
-
-
84890254448
-
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
-
Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997-4013 (2013).
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 3997-4013
-
-
Wolff, A.C.1
-
8
-
-
2942623615
-
Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer
-
Esteva, F. J. Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. Oncologist 9, 4-9 (2004).
-
(2004)
Oncologist
, vol.9
, pp. 4-9
-
-
Esteva, F.J.1
-
9
-
-
76549090842
-
Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
-
Morrow, P. K., Zambrana, F. & Esteva, F. J. Recent advances in systemic therapy: advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res. 11, 207 (2009).
-
(2009)
Breast Cancer Res.
, vol.11
, pp. 207
-
-
Morrow, P.K.1
Zambrana, F.2
Esteva, F.J.3
-
10
-
-
0034470522
-
Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer
-
Fornier, M., Esteva, F. J. & Seidman, A. D. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin. Oncol. 27, 38-45 (2000).
-
(2000)
Semin. Oncol.
, vol.27
, pp. 38-45
-
-
Fornier, M.1
Esteva, F.J.2
Seidman, A.D.3
-
11
-
-
84905841417
-
Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update
-
Burstein, H. J. et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J. Clin. Oncol. 32, 2255-2269 (2014).
-
(2014)
J. Clin. Oncol.
, vol.32
, pp. 2255-2269
-
-
Burstein, H.J.1
-
12
-
-
0035865149
-
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer
-
Ravdin, P. M. et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol. 19, 980-991 (2001).
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 980-991
-
-
Ravdin, P.M.1
-
13
-
-
84926139019
-
Biological subtypes of breast cancer: Prognostic and therapeutic implications
-
Yersal, O. & Barutca, S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J. Clin. Oncol. 5, 412-424 (2014).
-
(2014)
World J. Clin. Oncol.
, vol.5
, pp. 412-424
-
-
Yersal, O.1
Barutca, S.2
-
14
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
-
Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
-
(2005)
Lancet
, vol.365
, pp. 1687-1717
-
-
-
15
-
-
85203363507
-
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials
-
Early Breast Cancer Trialists' Collaborative Group et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771-784 (2011).
-
(2011)
Lancet
, vol.378
, pp. 771-784
-
-
-
16
-
-
84856636292
-
Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials
-
Early Breast Cancer Trialists' Collaborative Group et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379, 432-444 (2012).
-
(2012)
Lancet
, vol.379
, pp. 432-444
-
-
-
17
-
-
0034680102
-
Molecular portraits of human breast tumours
-
Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
-
(2000)
Nature
, vol.406
, pp. 747-752
-
-
Perou, C.M.1
-
18
-
-
66849140730
-
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
-
Cheang, M. C. et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst. 101, 736-750 (2009).
-
(2009)
J. Natl Cancer Inst.
, vol.101
, pp. 736-750
-
-
Cheang, M.C.1
-
19
-
-
0042838307
-
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
-
Sotiriou, C. et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100, 10393-10398 (2003).
-
(2003)
Proc. Natl Acad. Sci. USA
, vol.100
, pp. 10393-10398
-
-
Sotiriou, C.1
-
20
-
-
23844549918
-
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
-
Rouzier, R. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11, 5678-5685 (2005).
-
(2005)
Clin. Cancer Res.
, vol.11
, pp. 5678-5685
-
-
Rouzier, R.1
-
21
-
-
78049308800
-
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
-
Prat, A. et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12, R68 (2010).
-
(2010)
Breast Cancer Res.
, vol.12
, pp. R68
-
-
Prat, A.1
-
22
-
-
84963558666
-
Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline
-
Harris, L. N. et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 34, 1134-1150 (2016).
-
(2016)
J. Clin. Oncol.
, vol.34
, pp. 1134-1150
-
-
Harris, L.N.1
-
23
-
-
59849108152
-
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: Methods of the EGAPP Working Group
-
Teutsch, S. M. et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet. Med. 11, 3-14 (2009).
-
(2009)
Genet. Med.
, vol.11
, pp. 3-14
-
-
Teutsch, S.M.1
-
24
-
-
77951482885
-
Outcomes of interest in evidence-based evaluations of genetic tests
-
Botkin, J. R. et al. Outcomes of interest in evidence-based evaluations of genetic tests. Genet. Med. 12, 228-235 (2010).
-
(2010)
Genet. Med.
, vol.12
, pp. 228-235
-
-
Botkin, J.R.1
-
25
-
-
19944422061
-
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
-
Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
-
(2004)
N. Engl. J. Med.
, vol.351
, pp. 2817-2826
-
-
Paik, S.1
-
26
-
-
1842573771
-
Tumor gene expression and prognosis in breast cancer: Multi-gene RT-PCR assay of paraffin-embedded tissue [abstract]
-
Esteban, J. et al. Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue [abstract]. Proc. Am. Soc. Clin. Oncol. 22, 850 (2003).
-
(2003)
Proc. Am. Soc. Clin. Oncol.
, vol.22
, pp. 850
-
-
Esteban, J.1
-
27
-
-
1042284395
-
Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: High throughout RT-PCR assay of paraffin-embedded tumor tissues [abstract]
-
Cobleigh, M. A. et al. Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: high throughout RT-PCR assay of paraffin-embedded tumor tissues [abstract]. Proc. Am. Soc. Clin. Oncol. 22, 850 (2003).
-
(2003)
Proc. Am. Soc. Clin. Oncol.
, vol.22
, pp. 850
-
-
Cobleigh, M.A.1
-
28
-
-
1842573772
-
Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients - NSABP studies B-20 and B-14
-
Paik, S. et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients - NSABP studies B-20 and B-14. Breast Cancer Res. Treat. 82, A16 (2003).
-
(2003)
Breast Cancer Res. Treat.
, vol.82
, pp. A16
-
-
Paik, S.1
-
29
-
-
20944432470
-
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy
-
Esteva, F. J. et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin. Cancer Res. 11, 3315-3319 (2005).
-
(2005)
Clin. Cancer Res.
, vol.11
, pp. 3315-3319
-
-
Esteva, F.J.1
-
30
-
-
33744814477
-
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
-
Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726-3734 (2006).
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 3726-3734
-
-
Paik, S.1
-
31
-
-
51749093141
-
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197
-
Goldstein, L. J. et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J. Clin. Oncol. 26, 4092-4099 (2008).
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 4092-4099
-
-
Goldstein, L.J.1
-
32
-
-
51649110952
-
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features
-
Goldstein, L. J. et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J. Clin. Oncol. 26, 4063-4071 (2008).
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 4063-4071
-
-
Goldstein, L.J.1
-
33
-
-
77951637777
-
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study
-
Dowsett, M. et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J. Clin. Oncol. 28, 1829-1834 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 1829-1834
-
-
Dowsett, M.1
-
34
-
-
84928572844
-
Biomarker validation and testing
-
Hayes, D. F. Biomarker validation and testing. Mol. Oncol. 9, 960-966 (2015).
-
(2015)
Mol. Oncol.
, vol.9
, pp. 960-966
-
-
Hayes, D.F.1
-
35
-
-
33750895236
-
TAILORx: Trial assigning individualized options for treatment (Rx)
-
Sparano, J. A. TAILORx: trial assigning individualized options for treatment (Rx). Clin. Breast Cancer 7, 347-350 (2006).
-
(2006)
Clin. Breast Cancer
, vol.7
, pp. 347-350
-
-
Sparano, J.A.1
-
36
-
-
84947730258
-
Prospective validation of a 21-gene expression assay in breast cancer
-
Sparano, J. A. et al. Prospective validation of a 21-gene expression assay in breast cancer. N. Engl. J. Med. 373, 2005-2014 (2015).
-
(2015)
N. Engl. J. Med.
, vol.373
, pp. 2005-2014
-
-
Sparano, J.A.1
-
37
-
-
62449131093
-
Supervised risk predictor of breast cancer based on intrinsic subtypes
-
Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 1160-1167
-
-
Parker, J.S.1
-
38
-
-
83455203587
-
NanoStriDE: Normalization and differential expression analysis of NanoString nCounter data
-
Brumbaugh, C. D., Kim, H. J., Giovacchini, M. & Pourmand, N. NanoStriDE: normalization and differential expression analysis of NanoString nCounter data. BMC Bioinformatics 12, 479 (2011).
-
(2011)
BMC Bioinformatics
, vol.12
, pp. 479
-
-
Brumbaugh, C.D.1
Kim, H.J.2
Giovacchini, M.3
Pourmand, N.4
-
39
-
-
33749030177
-
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
-
Hess, K. R. et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24, 4236-4244 (2006).
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 4236-4244
-
-
Hess, K.R.1
-
40
-
-
0035224451
-
Expression of ErbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry
-
Esteva, F. J. et al. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol. Oncol. Res. 7, 171-177 (2001).
-
(2001)
Pathol. Oncol. Res.
, vol.7
, pp. 171-177
-
-
Esteva, F.J.1
-
41
-
-
78049453780
-
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer
-
Nielsen, T. O. et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin. Cancer Res. 16, 5222-5232 (2010).
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 5222-5232
-
-
Nielsen, T.O.1
-
42
-
-
84893424611
-
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
-
Gnant, M. et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann. Oncol. 25, 339-345 (2014).
-
(2014)
Ann. Oncol.
, vol.25
, pp. 339-345
-
-
Gnant, M.1
-
43
-
-
18244409687
-
Gene expression profiling predicts clinical outcome of breast cancer
-
van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
-
(2002)
Nature
, vol.415
, pp. 530-536
-
-
Van 't Veer, L.J.1
-
44
-
-
0037137519
-
A gene-expression signature as a predictor of survival in breast cancer
-
van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
-
(2002)
N. Engl. J. Med.
, vol.347
, pp. 1999-2009
-
-
Van De Vijver, M.J.1
-
45
-
-
84894092094
-
Long-term impact of the 70-gene signature on breast cancer outcome
-
Drukker, C. A. et al. Long-term impact of the 70-gene signature on breast cancer outcome. Breast Cancer Res. Treat. 143, 587-592 (2014).
-
(2014)
Breast Cancer Res. Treat.
, vol.143
, pp. 587-592
-
-
Drukker, C.A.1
-
46
-
-
33748693297
-
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
-
Buyse, M. et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98, 1183-1192 (2006).
-
(2006)
J. Natl Cancer Inst.
, vol.98
, pp. 1183-1192
-
-
Buyse, M.1
-
47
-
-
84878857125
-
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
-
Drukker, C. A. et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int. J. Cancer 133, 929-936 (2013).
-
(2013)
Int. J. Cancer
, vol.133
, pp. 929-936
-
-
Drukker, C.A.1
-
48
-
-
20444433297
-
-
Kwaliteitsinstituut voor de Gezondheidszorg CBO VvlK Richtlijn Behandeling van het Mammacarcinoom [Dutch]
-
Kwaliteitsinstituut voor de Gezondheidszorg CBO VvlK. Adjuvante Systemische Therapie voor het Operabel Mammacarcinoom. Richtlijn Behandeling van het Mammacarcinoom [Dutch]. 46-70 (2004).
-
(2004)
Adjuvante Systemische Therapie voor Het Operabel Mammacarcinoom
, pp. 46-70
-
-
-
49
-
-
80052418906
-
Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice
-
Bueno-De-Mesquita, J. M., Sonke, G. S., van de Vijver, M. J. & Linn, S. C. Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. Ann. Oncol. 22, 2021-2030 (2011).
-
(2011)
Ann. Oncol.
, vol.22
, pp. 2021-2030
-
-
Bueno-De-Mesquita, J.M.1
Sonke, G.S.2
Van De Vijver, M.J.3
Linn, S.C.4
-
50
-
-
49649114805
-
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort
-
Wittner, B. S. et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin. Cancer Res. 14, 2988-2993 (2008).
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 2988-2993
-
-
Wittner, B.S.1
-
51
-
-
84912011010
-
Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: A pooled analysis
-
Drukker, C. A. et al. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis. Breast Cancer Res. Treat. 148, 599-613 (2014).
-
(2014)
Breast Cancer Res. Treat.
, vol.148
, pp. 599-613
-
-
Drukker, C.A.1
-
52
-
-
67649183386
-
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study
-
Mook, S. et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res. Treat. 116, 295-302 (2009).
-
(2009)
Breast Cancer Res. Treat.
, vol.116
, pp. 295-302
-
-
Mook, S.1
-
53
-
-
77950862535
-
The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age
-
Mook, S. et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann. Oncol. 21, 717-722 (2010).
-
(2010)
Ann. Oncol.
, vol.21
, pp. 717-722
-
-
Mook, S.1
-
54
-
-
84884127326
-
Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4-9 positive lymph nodes
-
Saghatchian, M. et al. Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4-9 positive lymph nodes. Breast 22, 682-690 (2013).
-
(2013)
Breast
, vol.22
, pp. 682-690
-
-
Saghatchian, M.1
-
55
-
-
84894033527
-
MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue
-
Sapino, A. et al. MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. J. Mol. Diagn. 16, 190-197 (2014).
-
(2014)
J. Mol. Diagn.
, vol.16
, pp. 190-197
-
-
Sapino, A.1
-
56
-
-
79951818662
-
Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue
-
Mittempergher, L. et al. Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS ONE 6, e17163 (2011).
-
(2011)
PLoS ONE
, vol.6
, pp. e17163
-
-
Mittempergher, L.1
-
57
-
-
84984697640
-
70-gene signature as an aid to treatment decisions in early-stage breast cancer
-
Cardoso, F. et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med. 375, 717-729 (2016).
-
(2016)
N. Engl. J. Med.
, vol.375
, pp. 717-729
-
-
Cardoso, F.1
-
58
-
-
2942578063
-
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen
-
Ma, X. J. et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607-616 (2004).
-
(2004)
Cancer Cell
, vol.5
, pp. 607-616
-
-
Ma, X.J.1
-
59
-
-
52049095087
-
A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer
-
Ma, X. J. et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin. Cancer Res. 14, 2601-2608 (2008).
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 2601-2608
-
-
Ma, X.J.1
-
60
-
-
79957617088
-
Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial
-
Jerevall, P. L. et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br. J. Cancer 104, 1762-1769 (2011).
-
(2011)
Br. J. Cancer
, vol.104
, pp. 1762-1769
-
-
Jerevall, P.L.1
-
61
-
-
84874931531
-
HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease
-
Habel, L. A. et al. HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease. Breast Cancer Res. 15, R24 (2013).
-
(2013)
Breast Cancer Res.
, vol.15
, pp. R24
-
-
Habel, L.A.1
-
62
-
-
7444259675
-
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
-
Goss, P. E. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793-1802 (2003).
-
(2003)
N. Engl. J. Med.
, vol.349
, pp. 1793-1802
-
-
Goss, P.E.1
-
64
-
-
84880515409
-
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker
-
Sgroi, D. C. et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J. Natl Cancer Inst. 105, 1036-1042 (2013).
-
(2013)
J. Natl Cancer Inst.
, vol.105
, pp. 1036-1042
-
-
Sgroi, D.C.1
-
65
-
-
80052845090
-
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors
-
Filipits, M. et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 17, 6012-6020 (2011).
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 6012-6020
-
-
Filipits, M.1
-
66
-
-
84866973653
-
Decentral gene expression analysis: Analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test
-
Kronenwett, R. et al. Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer 12, 456 (2012).
-
(2012)
BMC Cancer
, vol.12
, pp. 456
-
-
Kronenwett, R.1
-
67
-
-
84874570581
-
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
-
Dubsky, P. et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann. Oncol. 24, 640-647 (2013).
-
(2013)
Ann. Oncol.
, vol.24
, pp. 640-647
-
-
Dubsky, P.1
-
68
-
-
84890426904
-
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2-breast cancer patients
-
Dubsky, P. et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2-breast cancer patients. Br. J. Cancer 109, 2959-2964 (2013).
-
(2013)
Br. J. Cancer
, vol.109
, pp. 2959-2964
-
-
Dubsky, P.1
-
69
-
-
0037445117
-
Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6
-
Schmid, M. et al. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. J. Clin. Oncol. 21, 984-990 (2003).
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 984-990
-
-
Schmid, M.1
-
70
-
-
23444446523
-
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial
-
Jakesz, R. et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366, 455-462 (2005).
-
(2005)
Lancet
, vol.366
, pp. 455-462
-
-
Jakesz, R.1
-
71
-
-
84902257708
-
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2-breast cancer patients: Results from the GEICAM 9906 trial
-
Martin, M. et al. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2-breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Res. 16, R38 (2014).
-
(2014)
Breast Cancer Res.
, vol.16
, pp. R38
-
-
Martin, M.1
-
72
-
-
81155133281
-
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer
-
Cuzick, J. et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J. Clin. Oncol. 29, 4273-4278 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 4273-4278
-
-
Cuzick, J.1
-
73
-
-
84891459472
-
An international Ki67 reproducibility study
-
Polley, M. Y. et al. An international Ki67 reproducibility study. J. Natl Cancer Inst. 105, 1897-1906 (2013).
-
(2013)
J. Natl Cancer Inst.
, vol.105
, pp. 1897-1906
-
-
Polley, M.Y.1
-
74
-
-
33144462268
-
Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis
-
Sotiriou, C. et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst. 98, 262-272 (2006).
-
(2006)
J. Natl Cancer Inst.
, vol.98
, pp. 262-272
-
-
Sotiriou, C.1
-
75
-
-
34247145491
-
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
-
Loi, S. et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol. 25, 1239-1246 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 1239-1246
-
-
Loi, S.1
-
76
-
-
67650327607
-
Genomic grade index is associated with response to chemotherapy in patients with breast cancer
-
Liedtke, C. et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J. Clin. Oncol. 27, 3185-3191 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 3185-3191
-
-
Liedtke, C.1
-
77
-
-
33746910265
-
Concordance among gene-expression-based predictors for breast cancer
-
Fan, C. et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355, 560-569 (2006).
-
(2006)
N. Engl. J. Med.
, vol.355
, pp. 560-569
-
-
Fan, C.1
-
78
-
-
0037478605
-
Repeated observation of breast tumor subtypes in independent gene expression data sets
-
Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418-8423 (2003).
-
(2003)
Proc. Natl Acad. Sci. USA
, vol.100
, pp. 8418-8423
-
-
Sorlie, T.1
-
79
-
-
20144386127
-
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival
-
Chang, H. Y. et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl Acad. Sci. USA 102, 3738-3743 (2005).
-
(2005)
Proc. Natl Acad. Sci. USA
, vol.102
, pp. 3738-3743
-
-
Chang, H.Y.1
-
80
-
-
19344363035
-
Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds
-
Chang, H. Y. et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2, E7 (2004).
-
(2004)
PLoS Biol.
, vol.2
, pp. E7
-
-
Chang, H.Y.1
-
81
-
-
58149330982
-
Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures
-
Wirapati, P. et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10, R65 (2008).
-
(2008)
Breast Cancer Res.
, vol.10
, pp. R65
-
-
Wirapati, P.1
-
82
-
-
84884762173
-
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy
-
Dowsett, M. et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J. Clin. Oncol. 31, 2783-2790 (2013).
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 2783-2790
-
-
Dowsett, M.1
-
83
-
-
78449291165
-
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers
-
Kelly, C. M. et al. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116, 5161-5167 (2010).
-
(2010)
Cancer
, vol.116
, pp. 5161-5167
-
-
Kelly, C.M.1
-
84
-
-
84860150463
-
Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier in early-stage estrogen receptor-positive breast cancer
-
Kelly, C. M. et al. Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier in early-stage estrogen receptor-positive breast cancer. Oncologist 17, 492-498 (2012).
-
(2012)
Oncologist
, vol.17
, pp. 492-498
-
-
Kelly, C.M.1
-
85
-
-
84884704047
-
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: A prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
-
Sgroi, D. C. et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 14, 1067-1076 (2013).
-
(2013)
Lancet Oncol.
, vol.14
, pp. 1067-1076
-
-
Sgroi, D.C.1
-
86
-
-
85003047281
-
The Genomic Grade assay compared with Ki67 to determine risk of distant breast cancer recurrence
-
Ignatiadis, M. et al. The Genomic Grade assay compared with Ki67 to determine risk of distant breast cancer recurrence. JAMA Oncol. 2, 217-224 (2016).
-
(2016)
JAMA Oncol.
, vol.2
, pp. 217-224
-
-
Ignatiadis, M.1
-
87
-
-
29544433211
-
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
-
Breast International Group (BIG) 1-98 Collaborative Group et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2757 (2005).
-
(2005)
N. Engl. J. Med.
, vol.353
, pp. 2747-2757
-
-
-
88
-
-
84989180539
-
Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: No test is more equal than the others
-
Bartlett, J. M. et al. Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others. J. Natl Cancer Inst. 108, djw050 (2016).
-
(2016)
J. Natl Cancer Inst.
, vol.108
, pp. djw050
-
-
Bartlett, J.M.1
-
89
-
-
85023764496
-
Comprehensive comparison of prognostic signatures for breast cancer in TransATAC [abstract]
-
Abstr. S6-05
-
Sestack, I. et al. Comprehensive comparison of prognostic signatures for breast cancer in TransATAC [abstract]. 2016 San Antonio Breast Cancer Symposium (SABCS). Abstr. S6-05 (2016).
-
(2016)
2016 San Antonio Breast Cancer Symposium (SABCS)
-
-
Sestack, I.1
-
90
-
-
18444383684
-
Population-based validation of the prognostic model ADJUVANT! for early breast cancer
-
Bajdik, I. A. et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J. Clin. Oncol. 23, 2716-2725 (2005).
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 2716-2725
-
-
Bajdik, I.A.1
-
91
-
-
84887989400
-
Prospective cost-effectiveness analysis of genomic profiling in breast cancer
-
Retel, V. P. et al. Prospective cost-effectiveness analysis of genomic profiling in breast cancer. Eur. J. Cancer 49, 3773-3779 (2013).
-
(2013)
Eur. J. Cancer
, vol.49
, pp. 3773-3779
-
-
Retel, V.P.1
-
92
-
-
84863723973
-
Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
-
Lamond, N. W., Skedgel, C., Rayson, D., Lethbridge, L. & Younis, T. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res. Treat. 133, 1115-1123 (2012).
-
(2012)
Breast Cancer Res. Treat.
, vol.133
, pp. 1115-1123
-
-
Lamond, N.W.1
Skedgel, C.2
Rayson, D.3
Lethbridge, L.4
Younis, T.5
-
93
-
-
33947196825
-
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: An economic analysis based on prognostic and predictive validation studies
-
Lyman, G. H., Cosler, L. E., Kuderer, N. M. & Hornberger, J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109, 1011-1018 (2007).
-
(2007)
Cancer
, vol.109
, pp. 1011-1018
-
-
Lyman, G.H.1
Cosler, L.E.2
Kuderer, N.M.3
Hornberger, J.4
-
94
-
-
79957823551
-
Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer
-
Chen, E., Tong, K. B. & Malin, J. L. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer. Am. J. Manag. Care 16, e333-e342 (2010).
-
(2010)
Am. J. Manag. Care
, vol.16
, pp. e333-e342
-
-
Chen, E.1
Tong, K.B.2
Malin, J.L.3
-
95
-
-
77951938304
-
Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer
-
Retel, V. P. et al. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur. J. Cancer 46, 1382-1391 (2010).
-
(2010)
Eur. J. Cancer
, vol.46
, pp. 1382-1391
-
-
Retel, V.P.1
-
96
-
-
84885136402
-
Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: A systematic review and cost-effectiveness analysis
-
Ward, S. et al. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis. Health Technol. Assess. 17, 1-302 (2013).
-
(2013)
Health Technol. Assess.
, vol.17
, pp. 1-302
-
-
Ward, S.1
-
97
-
-
84879767780
-
Multigene assays and molecular markers in breast cancer: Systematic review of health economic analyses
-
Rouzier, R. et al. Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Res. Treat. 139, 621-637 (2013).
-
(2013)
Breast Cancer Res. Treat.
, vol.139
, pp. 621-637
-
-
Rouzier, R.1
-
98
-
-
84867334350
-
Cost effectiveness of gene expression profiling for early stage breast cancer: A decision-analytic model
-
Yang, M., Rajan, S. & Issa, A. M. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model. Cancer 118, 5163-5170 (2012).
-
(2012)
Cancer
, vol.118
, pp. 5163-5170
-
-
Yang, M.1
Rajan, S.2
Issa, A.M.3
-
99
-
-
0029866092
-
On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993
-
Griffin, A. M. et al. On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann. Oncol. 7, 189-195 (1996).
-
(1996)
Ann. Oncol.
, vol.7
, pp. 189-195
-
-
Griffin, A.M.1
-
100
-
-
84874572643
-
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group consensus statement
-
Azim, H. A. Jr et al. Utility of prognostic genomic tests in breast cancer practice: the IMPAKT 2012 Working Group consensus statement. Ann. Oncol. 24, 647-654 (2013).
-
(2013)
Ann. Oncol.
, vol.24
, pp. 647-654
-
-
Azim, H.A.1
-
101
-
-
36849069347
-
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
-
Harris, L. et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25, 5287-5312 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 5287-5312
-
-
Harris, L.1
-
102
-
-
84876691969
-
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
-
Harbeck, N. et al. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur. J. Cancer 49, 1825-1835 (2013).
-
(2013)
Eur. J. Cancer
, vol.49
, pp. 1825-1835
-
-
Harbeck, N.1
-
103
-
-
58149183234
-
Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials
-
Ross, D. T. et al. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Clin. Cancer Res. 14, 6602-6609 (2008).
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 6602-6609
-
-
Ross, D.T.1
-
104
-
-
51349088017
-
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
-
Desmedt, C. et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14, 5158-5165 (2008).
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 5158-5165
-
-
Desmedt, C.1
-
105
-
-
84875722651
-
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98
-
Loi, S. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol. 31, 860-867 (2013).
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 860-867
-
-
Loi, S.1
-
106
-
-
84905178989
-
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial
-
Loi, S. et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol. 25, 1544-1550 (2014).
-
(2014)
Ann. Oncol.
, vol.25
, pp. 1544-1550
-
-
Loi, S.1
-
107
-
-
72149104757
-
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: A phase 3, open-label, randomised controlled trial
-
Albain, K. S. et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374, 2055-2063 (2009).
-
(2009)
Lancet
, vol.374
, pp. 2055-2063
-
-
Albain, K.S.1
-
108
-
-
84892795827
-
Breast cancer statistics, 2013
-
DeSantis, C., Ma, J., Bryan, L. & Jemal, A. Breast cancer statistics, 2013. CA Cancer J. Clin. 64, 52-62 (2014).
-
(2014)
CA Cancer J. Clin.
, vol.64
, pp. 52-62
-
-
DeSantis, C.1
Ma, J.2
Bryan, L.3
Jemal, A.4
-
109
-
-
0038662715
-
Participation of patients 65 years of age or older in cancer clinical trials
-
Lewis, J. H. et al. Participation of patients 65 years of age or older in cancer clinical trials. J. Clin. Oncol. 21, 1383-1389 (2003).
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 1383-1389
-
-
Lewis, J.H.1
-
110
-
-
84858165551
-
The EORTC Cancer in the Elderly Task Force, a Protostar for EORTC's future
-
Wildiers, H. et al. The EORTC Cancer in the Elderly Task Force, a Protostar for EORTC's future. Eur. J. Cancer 10, 34-38 (2012).
-
(2012)
Eur. J. Cancer
, vol.10
, pp. 34-38
-
-
Wildiers, H.1
|